Advances in Stem Cell Transplantation for Myelofibrosis

2024-9-6

Systemic Mastocytosis: State of the Art

2024-8-27

Prognostic and Predictive Models in Myelofibrosis

2024-8-24

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma

2024-8-15

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals

2024-7-22

Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia

2024-7-6

MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications

2024-6-18

Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection

2024-6-13

Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies

2024-5-29

Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

2024-5-18

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

2024-4-18

Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia

2024-3-27

Update on T-Cell Lymphoma Epidemiology

2024-3-7

Management of Patients with Early Myelofibrosis: A Discussion of Best Practices

2024-3-5

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions

2024-2-23

Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations

2024-2-19

Frontline Therapy of CLL—Changing Treatment Paradigms

2024-2-10

Transplantation and Cellular Therapy for Older Adults—The MSK Approach

2024-2-9

Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders

2024-2-5

How Do We Manage Chronic Lymphocytic Leukemia in India

2024-2-1

Treatment of Richter’s Transformation with Novel Therapies

2024-1-9

Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders

2023-12-30

Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders

2023-12-14

Blinatumomab in Practice

2023-12-7

Novel Biomarkers and Molecular Targets in ALL

2023-12-4

Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes

2023-11-24

Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions

2023-11-10

Measurable Residual Disease Monitoring in Lymphoma

2023-11-6

Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders

2023-10-23

Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders

2023-10-3

NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition

2023-9-26

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia

2023-8-31

Central Nervous System Relapse in T and NK cell Lymphomas

2023-8-25

EBV Reactivation and Lymphomagenesis: More Questions than Answers

2023-8-11

Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions

2023-7-25

Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma

2023-7-25

Multiple Myeloma: Current Clinical Landscape and Compounding Costs

2023-7-21

Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma

2023-7-4

A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases

2023-7-3

Real-world Management of CML: Outcomes and Treatment Patterns

2023-7-3

Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress?

2023-6-9

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

2023-6-6

Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations

2023-6-1

GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation

2023-5-29

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer

2023-5-24

Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis

2023-5-17

A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment

2023-5-16

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

2023-4-13

New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications

2023-4-5

Managing Survivorship after Hematopoietic Cell Transplantation

2023-3-30